氟伏沙明与安慰剂对轻中度COVID-19门诊患者持续恢复时间的影响:一项随机临床试验
该研究为ACTIV-6平台随机临床试验,纳入1288例轻中度COVID-19门诊患者,比较氟伏沙明50 mg每日两次连用10天与安慰剂的疗效。结果显示,氟伏沙明组持续恢复中位时间12天,安慰剂组13天(HR 0.96,95%可信区间0.86-1.06),复合结局无显著差异。结论认为该剂量和疗程的氟伏沙明不改善持续恢复时间。
要点
- 氟伏沙明组持续恢复中位时间12天,安慰剂组13天,HR 0.96(95%可信区间0.86-1.06)。
- 复合结局(住院、急诊就诊、紧急护理或死亡)氟伏沙明组3.9% vs 安慰剂组3.8%,HR 1.1(95%可信区间0.5-1.8)。
- 两组不良事件均不常见,氟伏沙明组1例住院,安慰剂组2例住院,无死亡。
核心结论
- 在轻中度COVID-19门诊患者中,与安慰剂相比,氟伏沙明50 mg每日两次连用10天未改善持续恢复时间。
- 这些发现不支持在轻中度COVID-19患者中使用此剂量和疗程的氟伏沙明。
研究设计与样本
- ACTIV-6平台随机临床试验,在美国91个中心进行。
- 2021年8月6日至2022年5月27日期间纳入1288例年龄≥30岁、确诊SARS-CoV-2感染且急性COVID-19症状≥2项持续≤7天的门诊患者。
- 参与者随机接受氟伏沙明50 mg每日两次连用10天或安慰剂。
- 共1331例参与者随机分组(中位年龄47岁,IQR 38-57岁;57%为女性;67%报告接种≥2剂SARS-CoV-2疫苗),1288例完成试验(氟伏沙明组674例,安慰剂组614例)。
主要发现
- 持续恢复中位时间:氟伏沙明组12天(IQR 11-14天)vs 安慰剂组13天(IQR 12-13天),HR 0.96(95%可信区间0.86-1.06),posterior P=0.21(获益概率,以HR>1判定)。
- 复合结局(住院、紧急护理就诊、急诊就诊或死亡)至第28天:氟伏沙明组26例(3.9%)vs 安慰剂组23例(3.8%),HR 1.1(95%可信区间0.5-1.8),posterior P=0.35(获益概率,以HR<1判定)。
- 住院:氟伏沙明组1例,安慰剂组2例;两组均无死亡。
- 不良事件在两组均不常见。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. OBJECTIVE: To evaluate the efficacy of low-dose fluvoxamine (50 mg twice daily) for 10 days compared with placebo for the treatment of mild to moderate COVID-19 in the US. DESIGN, SETTING, AND PARTICIPANTS: The ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) platform randomized clinical trial was designed to test repurposed medications in outpatients with mild to moderate COVID-19. A total of 1288 participants aged 30 years or older with test-confirmed SARS-CoV-2 infection and experiencing 2 or more symptoms of acute COVID-19 for 7 days or less were enrolled between August 6, 2021, and May 27, 2022, at 91 sites in the US. INTERVENTIONS: Participants were randomized to receive 50 mg of fluvoxamine twice daily for 10 days or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was time to sustained recovery (defined as the third day of 3 consecutive days without symptoms). There were 7 secondary outcomes, including a composite outcome of hospitalization, urgent care visit, emergency department visit, or death through day 28. RESULTS: Among 1331 participants who were randomized (median age, 47 years [IQR, 38-57 years]; 57% were women; and 67% reported receiving ≥2 doses of a SARS-CoV-2 vaccine), 1288 completed the trial (674 in the fluvoxamine group and 614 in the placebo group). The median time to sustained recovery was 12 days (IQR, 11-14 days) in the fluvoxamine group and 13 days (IQR, 12-13 days) in the placebo group (hazard ratio [HR], 0.96 [95% credible interval, 0.86-1.06], posterior P = .21 for the probability of benefit [determined by an HR >1]). For the composite outcome, 26 participants (3.9%) in the fluvoxamine group were hospitalized, had an urgent care visit, had an emergency department visit, or died compared with 23 participants (3.8%) in the placebo group (HR, 1.1 [95% credible interval, 0.5-1.8], posterior P = .35 for the probability of benefit [determined by an HR <1]). One participant in the fluvoxamine group and 2 participants in the placebo group were hospitalized; no deaths occurred in either group. Adverse events were uncommon in both groups. CONCLUSIONS AND RELEVANCE: Among outpatients with mild to moderate COVID-19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04885530.
引用
- McCarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2023. PMID: 36633838. doi:10.1001/jama.2022.24100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。